Yoshida S O, Imam A, Olson C A, Taylor C R
Arch Pathol Lab Med. 1986 Sep;110(9):825-32.
Polyclonal antibodies to the brush border membrane of the human renal proximal tubule were found to identify two proteins with apparent molecular weights of 35,000 and 46,000 daltons. The antigens are distinct in their molecular weights from other antigens that have been localized to the human proximal tubular brush border. The antibodies were extensively studied for their immunoreactivity to fixed, embedded tissue sections by indirect immunoperoxidase staining. These sections were from 36 primary and 37 metastatic renal cell carcinomas, three renal oncocytomas, 87 cases of 28 different types of neoplasms, and 33 different types of normal tissues. Ninety-four percent of primary and 78% of metastatic renal cell carcinomas demonstrated expression of the antigens. Eight cases in which both primary tumor and its metastases were available revealed a general quantitative decrease in expression of the antigens in the metastases. Specificity analysis revealed immunoreactivity to the luminal surfaces of cells lining the epididymis, breast lobule, and bile ductules; the cytoplasm of the submandibular gland ductules; and to some adenocarcinomas of lung, breast, and small intestine, astrocytomas of brain, and squamous carcinomas of skin. The antibodies may be of some utility in the surgical pathology laboratory to help determine the primary site of metastatic clear cell tumors and may also be of use in the in vitro differentiation of renal epithelial cells. Development of monoclonal antibodies to these antigens may improve specificity and clinical utility.
已发现针对人肾近端小管刷状缘膜的多克隆抗体可识别两种表观分子量分别为35,000和46,000道尔顿的蛋白质。这些抗原在分子量上与已定位到人近端小管刷状缘的其他抗原不同。通过间接免疫过氧化物酶染色,对这些抗体与固定、包埋组织切片的免疫反应性进行了广泛研究。这些切片来自36例原发性和37例转移性肾细胞癌、3例肾嗜酸细胞瘤、87例28种不同类型的肿瘤以及33种不同类型的正常组织。94%的原发性肾细胞癌和78%的转移性肾细胞癌显示出抗原表达。在8例同时有原发性肿瘤及其转移灶的病例中,转移灶中抗原表达普遍出现定量下降。特异性分析显示,抗体与附睾、乳腺小叶和胆小管内衬细胞的腔面、下颌下腺导管的细胞质以及一些肺、乳腺和小肠腺癌、脑星形细胞瘤和皮肤鳞状细胞癌有免疫反应性。这些抗体在外科病理实验室可能有助于确定转移性透明细胞肿瘤的原发部位,也可用于肾上皮细胞的体外分化。针对这些抗原开发单克隆抗体可能会提高特异性和临床应用价值。